Patient Satisfaction and Sensory Attributes Allergic Rhinitis Nasal Spray

Community and Patient Preference Research Pty Ltd426 enrolled

Overview

The study seeks to understand patients' satisfaction and importance of treatment attributes for Allergic Rhinitis nasal sprays from two brands (RYALTRIS® vs. DYMISTA®).

The study seeks to understand patients' satisfaction and importance of treatment attributes for Allergic Rhinitis nasal sprays from two brands (RYALTRIS® vs. DYMISTA®). To directly compare patient satisfaction with 2 different Allergic Rhinitis nasal sprays, an observational, cross-sectional study design with 2 independent samples was chosen. Participants will complete an online survey involving a Best-Worst scaling (BWS) task to determine satisfaction and importance index for sensory attributes. The suggested treatment attributes are informed by a range of previous studies, including those conducted by Meltzer et al 2005 and Price et al 2020, and methodology from CaPPRe's own work in developing indices for importance and satisfaction of treatment attributes using BWS.

Study Type

OBSERVATIONAL

Enrollment

426

Conditions

Allergic Rhinitis

Interventions

ObservationalOTHER

In this observational study, participants initated on RYALTRIS/DYMISTA nasal spray will complete a cross-sectional online survey that includes a Best-Worst Scaling task to capture their satisfaction and importance of various treatment attributes.

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: Allergic Rhinitis patients (moderate-to-severe Seasonal Allergic Rhinitis or Perennial Allergic Rhinitis) with or without conjunctivitis who meet the following criteria will be offered the opportunity to participate in the study: * Patients above 18 years old * Fluent in English * Patients initiated on RYALTRIS® or DYMISTA® nasal spray in the last 12 months and currently using treatment * Willing and able to provide consent to participate Exclusion Criteria: * Have reported a loss of taste and/or smell related to COVID-19 (or other medical condition) * Are employed by a pharmaceutical company (to avoid conflict of interest) * Are employed by a vaccine company (to avoid conflict of interest) * Do not have access to the internet (to ensure validity of the data) * Are unable to read and understand English (to ensure validity of the data)

Locations (1)

Community and Patient Preference Research Pty Ltd

Sydney, New South Wales, Australia

Outcomes

Primary Outcomes

Overall Best-Worst Scaling Task Index Score (Treatment Satisfaction Index Score)

The primary study endpoint is the overall index score from the Best Worst Scaling exercise, to reflect satisfaction and importance of treatment attributes of the RYALTRIS® and DYMISTA® nasal spray. Index scores from the Best Worst Scaling exercise range from 0 to 100, with higher scores indicating higher satisfaction of treatment attributes.

Time frame: Cross-sectional - through study completion, an average of 3 months

Secondary Outcomes

Rescaled Scores From Best-Worst Scaling Task

Secondary study endpoints were the rescaled Best Worst Scaling domain scores from the Best Worst Scaling exercise (i.e., scores for each of the domains on satisfaction and importance). Rescaled Best-Worst Scaling domain scores range from 0 to 10 and represent the satisfaction and importance of each domain. Higher satisfaction rescaled scores indicate higher satisfaction on a treatment attribute. Higher importance rescaled scores indicate higher importance of the treatment attribute. Higher rescaled satisfaction and importance scores suggest a better outcome since participants are satisfied and more likely to adhere to their current treatment.

Time frame: Cross-sectional - through study completion, an average of 3 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.